Pune, India, October, 2018 /press release/- Market Research Future Published a Half-Cooked Research Report on Gastrointestinal Drugs Market Research Report.
Gastrointestinal (GI) diseases affect the alimentary parts such as the stomach, large intestine, rectum, esophagus, liver, gallbladder and pancreas and is associated with symptoms such as heartburn, indigestion, bloating, and constipation. The global gastrointestinal drug market is projected to grow at CAGR of 4.8 % during the forecasted period of 2017 to 2023.
Growing incidence of GI diseases owing to rising risk factors is expected to drive a significant demand
According to World Gastroenterology Organization, 35 to 40 % of world’s population suffers from acute or chronic GI complication. The situation has been complicated by a rise in risk factors such as a change in dietary pattern, stress, infections especially by Helicobacter pylori, cancer, intake of fatty and spicy foods and others. Thus, a large and growing market is easily comprehensible.
Drug development and rising awareness are expected to drive a substantial growth
The development of highly efficacious and effective drugs such as the proton pump inhibitors (PPIs) with pronounced and long-lasting action and fewer to no side effects are driving the market. PPIs have superseded the other class of medications such as the H2-receptor antagonists and are among the most widely sold drugs globally.
Side effects associated with the drugs are restraining the market
The common adverse effects associated with gastrointestinal medications such as headache, nausea, diarrhea, abdominal pain, flatulence, constipation, fatigue, dizziness, and depression are the prime restraints of the market.
Segmentation To generate a better understanding of the global gastrointestinal drugs market, the report is segmented by drug category, route of administration, disease type, end user, and regions
Based on drug category, the market is segmented into Acid neutralizers, laxatives and antidiarrheal, antiemetic, anti-inflammatory drugs and other. Acid Neutralizers is further sub-segmented into Antacids, H2 antagonists, Proton pump inhibitors and Others,
Based on the route of administration, the market is segmented into oral, parenteral and rectal.
Based on disease type, the market is segmented into gastroesophageal reflux disease, inflammatory bowel disease and other.
Based on the end user, the market is segmented into hospital pharmacies, retail pharmacies and other.
Based on regions, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa.
North America led by the U.S. account for the most significant market share for the global gastrointestinal drug market owing to increasing geriatric population and massive healthcare expenditure. Europe is expected to be led by Germany, France, and the U.K.
The Asia Pacific is expected to be the fastest growing region led by China and India. The large population and growing economy are the prime drivers of the Asia Pacific region market. The European market. The Middle East and Africa market are expected to be dominated by Gulf economies of Saudi Arabia, UAE, Kuwait, and Qatar.
Some of the leading vendors in the global gastrointestinal drug market are AbbVie Inc. (US), AstraZeneca (UK), Johnson & Johnson (US), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), Janssen Biotech (US), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany).